These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10376979)

  • 21. Anti-tumoural activity of peripheral blood mononuclear cells against melanoma cells: discrepant in-vitro and in-vivo effects.
    Joseph-Pietras D; Carlier A; Madoulet C; Albert P
    Melanoma Res; 2006 Aug; 16(4):325-33. PubMed ID: 16845328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
    El-Khoury V; Gomez D; Liautaud-Roger F; Trussardi-Régnier A; Dufer J
    Cytometry A; 2004 Dec; 62(2):109-17. PubMed ID: 15517561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
    Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
    Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
    Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
    Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells.
    Burgess A; Ruefli A; Beamish H; Warrener R; Saunders N; Johnstone R; Gabrielli B
    Oncogene; 2004 Sep; 23(40):6693-701. PubMed ID: 15235588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
    Hollingshead M; Alley M; Burger AM; Borgel S; Pacula-Cox C; Fiebig HH; Sausville EA
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):115-25. PubMed ID: 15791458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate.
    Svechnikova I; Gray SG; Kundrotiene J; Ponthan F; Kogner P; Ekström TJ
    Int J Oncol; 2003 Mar; 22(3):579-88. PubMed ID: 12579311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
    Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
    Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Jin H; Wang M; Xiong K; Wright J; Young A
    Int J Oncol; 2006 Feb; 28(2):469-78. PubMed ID: 16391803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
    Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
    Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
    Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
    Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hollow fiber assay: continued characterization with novel approaches.
    Hall LA; Krauthauser CM; Wexler RS; Hollingshead MG; Slee AM; Kerr JS
    Anticancer Res; 2000; 20(2A):903-11. PubMed ID: 10810375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site.
    Gao J; Chen T; Liu J; Liu W; Hu G; Guo X; Yin B; Gong Y; Zhao J; Qiang B; Yuan J; Peng X
    Glia; 2009 Jul; 57(9):989-99. PubMed ID: 19062177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.